Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

49 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.
Snape MD, Perrett KP, Ford KJ, John TM, Pace D, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ. Snape MD, et al. Among authors: dull pm. JAMA. 2008 Jan 9;299(2):173-84. doi: 10.1001/jama.2007.29-c. JAMA. 2008. PMID: 18182599 Clinical Trial.
Safety and immunogenicity of an investigational quadrivalent meningococcal CRM(197) conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America.
Stamboulian D, Lopardo G, Lopez P, Cortes-Barbosa C, Valencia A, Bedell L, Karsten A, Dull PM. Stamboulian D, et al. Among authors: dull pm. Int J Infect Dis. 2010 Oct;14(10):e868-75. doi: 10.1016/j.ijid.2010.03.017. Epub 2010 Jul 22. Int J Infect Dis. 2010. PMID: 20655261 Clinical Trial.
Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age.
Black S, Klein NP, Shah J, Bedell L, Karsten A, Dull PM. Black S, et al. Among authors: dull pm. Vaccine. 2010 Jan 8;28(3):657-63. doi: 10.1016/j.vaccine.2009.10.104. Epub 2009 Nov 4. Vaccine. 2010. PMID: 19895922 Clinical Trial.
Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines.
Arguedas A, Soley C, Loaiza C, Rincon G, Guevara S, Perez A, Porras W, Alvarado O, Aguilar L, Abdelnour A, Grunwald U, Bedell L, Anemona A, Dull PM. Arguedas A, et al. Among authors: dull pm. Vaccine. 2010 Apr 19;28(18):3171-9. doi: 10.1016/j.vaccine.2010.02.045. Epub 2010 Feb 26. Vaccine. 2010. PMID: 20189491 Clinical Trial.
Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers.
Halperin SA, Diaz-Mitoma F, Dull P, Anemona A, Ceddia F. Halperin SA, et al. Among authors: dull p. Eur J Clin Microbiol Infect Dis. 2010 Mar;29(3):259-67. doi: 10.1007/s10096-009-0848-8. Epub 2009 Dec 22. Eur J Clin Microbiol Infect Dis. 2010. PMID: 20033465 Clinical Trial.
Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402].
Iro MA, Snape MD, Voysey M, Jawad S, Finn A, Heath PT, Bona G, Esposito S, Diez-Domingo J, Prymula R, Odueyungbo A, Toneatto D, Dull P, Pollard AJ; European Men B Vaccine Study Group. Iro MA, et al. Among authors: dull p. Vaccine. 2017 May 31;35(24):3279. doi: 10.1016/j.vaccine.2017.04.081. Epub 2017 May 5. Vaccine. 2017. PMID: 28483197 No abstract available.
Persistence of Meningococcal Antibodies and Response to a Third Dose After a Two-dose Vaccination Series with Investigational MenABCWY Vaccine Formulations in Adolescents.
Saez-Llorens X, Aguilera Vaca DC, Abarca K, Maho E, Han L, Smolenov I, Dull P. Saez-Llorens X, et al. Among authors: dull p. Pediatr Infect Dis J. 2015 Oct;34(10):e264-78. doi: 10.1097/INF.0000000000000822. Pediatr Infect Dis J. 2015. PMID: 26135245 Clinical Trial.
Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?
Hong E, Giuliani MM, Deghmane AE, Comanducci M, Brunelli B, Dull P, Pizza M, Taha MK. Hong E, et al. Among authors: dull p. Vaccine. 2013 Feb 4;31(7):1113-6. doi: 10.1016/j.vaccine.2012.12.022. Epub 2012 Dec 20. Vaccine. 2013. PMID: 23261039
Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials.
Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, Dull P, Kimura A; EU Meningococcal B Infant Vaccine Study group. Vesikari T, et al. Among authors: dull p. Lancet. 2013 Mar 9;381(9869):825-35. doi: 10.1016/S0140-6736(12)61961-8. Lancet. 2013. PMID: 23324563 Clinical Trial.
Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial.
Iro MA, Snape MD, Voysey M, Jawad S, Finn A, Heath PT, Bona G, Esposito S, Diez-Domingo J, Prymula R, Odueyungbo A, Toneatto D, Dull P, Pollard AJ; European Men B Vaccine Study Group. Iro MA, et al. Among authors: dull p. Vaccine. 2017 Jan 5;35(2):395-402. doi: 10.1016/j.vaccine.2016.11.009. Epub 2016 Nov 30. Vaccine. 2017. PMID: 27914744 Clinical Trial.
49 results
Jump to page
Feedback